<p>维京治疗公司（NASDAQ:VKTX - 获取免费报告）的股票在 BTIG 研究发布的报告中重申了 “买入” 评级，Benzinga 报道。他们目前对这家生物技术公司的股票设定了 125.00 美元的目标价。BTIG 研究的目标价暗示该股票当前价格有 316.67% 的潜在上涨空间。</p>
<p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
<ul>
<li>Viking Therapeutics 面临时间风险——但潜在收益可能巨大</li>
</ul>
<p>其他分析师最近也对该公司发布了报告。Cantor Fitzgerald 将 Viking Therapeutics 的目标价从 105.00 美元下调至 100.00 美元，并在周四的研究报告中给予该股票 “超配” 评级。Wolfe Research 在 3 月 26 日的研究报告中开始覆盖 Viking Therapeutics，并对该股票给予 “同业表现” 评级。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Viking Therapeutics 股票的 “卖出（d-）” 评级。摩根士丹利在周四对 Viking Therapeutics 设定了 95.00 美元的目标价。最后，HC Wainwright 在 3 月 23 日的报告中重申了 “买入” 评级，并设定了 102.00 美元的目标价。三位研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 95.50 美元。</p>
<p><strong>阅读我们关于 VKTX 的最新研究报告</strong></p>
<h2>Viking Therapeutics 股票表现</h2>
<ul>
<li>三家公司在 GLP-1 药物竞争中处于前沿</li>
</ul>
<p>NASDAQ VKTX 的股票在周五开盘价为 30.00 美元。该股票的市值为 34.8 亿美元，市盈率为-7.25，贝塔值为 0.72。Viking Therapeutics 的 12 个月低点为 22.96 美元，12 个月高点为 43.15 美元。该公司的 50 日简单移动平均线为 33.63 美元，200 日简单移动平均线为 34.02 美元。</p>
<p>Viking Therapeutics（NASDAQ:VKTX - 获取免费报告）最近在 4 月 29 日宣布了其季度财报。这家生物技术公司报告每股收益（EPS）为（1.37 美元），低于市场共识预期的（1.01 美元）0.36 美元。在去年同期，该公司每股收益为（0.41 美元）。分析师平均预测 Viking Therapeutics 在当前财年将发布-4.56 的每股收益。</p>
<h2>Viking Therapeutics 的内部活动</h2>
<ul>
<li>Viking Therapeutics：高风险的减肥竞争者</li>
</ul>
<p>在其他新闻中，内部人士 Neil William Aubuchon 在 3 月 10 日的交易中购买了 4475 股该公司的股票。这些股票的平均购买价格为每股 33.50 美元，总交易额为 149,912.50 美元。交易完成后，内部人士持有该公司 4475 股股票，价值约为 149,912.50 美元。这笔交易代表了他们持股的∞增长。该购买在与证券交易委员会的法律文件中披露，可以通过此链接访问。公司内部人士持有公司 5.30% 的股份。</p>
<h2>Viking Therapeutics 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Ameriprise Financial Inc.在第三季度将其在 Viking Therapeutics 的持仓增加了 41.8%。Ameriprise Financial Inc.现在拥有 2092840 股该生物技术公司的股票，价值 5500 万美元，此前在此期间又收购了 616526 股。Two Sigma Investments LP 在第三季度将其在 Viking Therapeutics 的持仓增加了 58.7%。Two Sigma Investments LP 现在拥有 2085487 股该生物技术公司的股票，价值 54807000 美元，此前在此期间又收购了 771704 股。Geode Capital Management LLC 在第四季度将其在 Viking Therapeutics 的持仓增加了 24.0%。Geode Capital Management LLC 现在拥有 1994509 股该生物技术公司的股票，价值 70183000 美元，此前在此期间又收购了 385903 股。BNP Paribas Financial Markets 在第四季度将其在 Viking Therapeutics 的持仓增加了 536.3%。BNP Paribas Financial Markets 现在拥有 992695 股该生物技术公司的股票，价值 34923000 美元，此前在此期间又收购了 836686 股。最后，Raymond James Financial Inc.在第三季度将其在 Viking Therapeutics 的持仓增加了 16.1%。Raymond James Financial Inc.现在拥有 954272 股该生物技术公司的股票，价值 25078000 美元，此前在此期间又收购了 131994 股。机构投资者和对冲基金持有公司 76.03% 的股份。</p>
<h2>Viking Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Viking Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。公司总部位于加利福尼亚州圣地亚哥，其产品线利用小分子方法针对与非酒精性脂肪性肝炎（NASH）、血脂异常、2 型糖尿病和肌肉萎缩疾病相关的激素信号通路。</p>
<p>该公司的主要项目包括 VK2809，一种设计用于减少肝脏脂肪并改善 NASH 和血脂异常患者的脂质谱的甲状腺激素受体β激动剂，以及 VK5211，一种选择性雄激素受体调节剂（SARM），旨在增强肌肉质量和功能，适用于肌肉萎缩患者。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Viking Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Viking Therapeutics 吗？</h2>
<p>在考虑 Viking Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Viking Therapeutics 并不在名单上。</p>
<p>虽然 Viking Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Viking治疗

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>BTIG Research 重申了对 Viking Therapeutics (VKTX) 的 “买入” 评级，目标价为 125.00 美元，意味着相较于当前价格有 316.67% 的潜在上涨空间。其他分析师的意见各不相同，Cantor Fitzgerald 将目标价下调至 100.00 美元，而 HC Wainwright 则维持在 102.00 美元的买入评级。该股票开盘价为 30.00 美元，市值为 34.8 亿美元。Viking 报告的季度每股收益为（1.37 美元），未能达到预期。机构投资者持有该股票的 76.03%，反映出对公司的强烈兴趣</p>

<p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report)'s stock had its &#34;buy&#34; rating restated by investment analysts at BTIG Research in a report issued on Friday,Benzinga reports. They currently have a $125.00 target price on the biotechnology company's stock. BTIG Research's price target suggests a potential upside of 316.67% from the stock's current price.</p>
<div class="lb-trans"><p>维京治疗公司（NASDAQ:VKTX - 获取免费报告）的股票在 BTIG 研究发布的报告中重申了 “买入” 评级，Benzinga 报道。他们目前对这家生物技术公司的股票设定了 125.00 美元的目标价。BTIG 研究的目标价暗示该股票当前价格有 316.67% 的潜在上涨空间。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 面临时间风险——但潜在收益可能巨大</li>
</ul>
</div><p>Other analysts have also recently issued reports about the company. Cantor Fitzgerald reduced their price objective on Viking Therapeutics from $105.00 to $100.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday. Wolfe Research assumed coverage on Viking Therapeutics in a research note on Thursday, March 26th. They issued a &#34;peer perform&#34; rating on the stock. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Viking Therapeutics in a research note on Monday, April 20th. Morgan Stanley set a $95.00 price target on Viking Therapeutics in a report on Thursday. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Monday, March 23rd. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $95.50.</p>
<div class="lb-trans"><p>其他分析师最近也对该公司发布了报告。Cantor Fitzgerald 将 Viking Therapeutics 的目标价从 105.00 美元下调至 100.00 美元，并在周四的研究报告中给予该股票 “超配” 评级。Wolfe Research 在 3 月 26 日的研究报告中开始覆盖 Viking Therapeutics，并对该股票给予 “同业表现” 评级。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Viking Therapeutics 股票的 “卖出（d-）” 评级。摩根士丹利在周四对 Viking Therapeutics 设定了 95.00 美元的目标价。最后，HC Wainwright 在 3 月 23 日的报告中重申了 “买入” 评级，并设定了 102.00 美元的目标价。三位研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 95.50 美元。</p>
</div><p><strong>Read Our Latest Research Report on VKTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 VKTX 的最新研究报告</strong></p>
</div><h2>Viking Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Viking Therapeutics 股票表现</h2>
</div><ul>
<li>3 Companies at the Forefront of the GLP-1 Pill Wars</li>
</ul>
<div class="lb-trans"><ul>
<li>三家公司在 GLP-1 药物竞争中处于前沿</li>
</ul>
</div><p>Shares of NASDAQ VKTX opened at $30.00 on Friday. The stock has a market cap of $3.48 billion, a P/E ratio of -7.25 and a beta of 0.72. Viking Therapeutics has a 12-month low of $22.96 and a 12-month high of $43.15. The business's fifty day simple moving average is $33.63 and its 200-day simple moving average is $34.02.</p>
<div class="lb-trans"><p>NASDAQ VKTX 的股票在周五开盘价为 30.00 美元。该股票的市值为 34.8 亿美元，市盈率为-7.25，贝塔值为 0.72。Viking Therapeutics 的 12 个月低点为 22.96 美元，12 个月高点为 43.15 美元。该公司的 50 日简单移动平均线为 33.63 美元，200 日简单移动平均线为 34.02 美元。</p>
</div><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.36). During the same quarter last year, the business posted ($0.41) earnings per share. On average, equities analysts forecast that Viking Therapeutics will post -4.56 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Viking Therapeutics（NASDAQ:VKTX - 获取免费报告）最近在 4 月 29 日宣布了其季度财报。这家生物技术公司报告每股收益（EPS）为（1.37 美元），低于市场共识预期的（1.01 美元）0.36 美元。在去年同期，该公司每股收益为（0.41 美元）。分析师平均预测 Viking Therapeutics 在当前财年将发布-4.56 的每股收益。</p>
</div><h2>Insider Activity at Viking Therapeutics</h2>
<div class="lb-trans"><h2>Viking Therapeutics 的内部活动</h2>
</div><ul>
<li>Viking Therapeutics: The High-Stakes Weight Loss Contender</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：高风险的减肥竞争者</li>
</ul>
</div><p>In other news, insider Neil William Aubuchon bought 4,475 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $33.50 per share, for a total transaction of $149,912.50. Following the completion of the transaction, the insider owned 4,475 shares of the company's stock, valued at approximately $149,912.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link. Company insiders own 5.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Neil William Aubuchon 在 3 月 10 日的交易中购买了 4475 股该公司的股票。这些股票的平均购买价格为每股 33.50 美元，总交易额为 149,912.50 美元。交易完成后，内部人士持有该公司 4475 股股票，价值约为 149,912.50 美元。这笔交易代表了他们持股的∞增长。该购买在与证券交易委员会的法律文件中披露，可以通过此链接访问。公司内部人士持有公司 5.30% 的股份。</p>
</div><h2>Institutional Trading of Viking Therapeutics</h2>
<div class="lb-trans"><h2>Viking Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. increased its position in Viking Therapeutics by 41.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company's stock valued at $55,000,000 after acquiring an additional 616,526 shares during the period. Two Sigma Investments LP increased its position in Viking Therapeutics by 58.7% in the 3rd quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company's stock valued at $54,807,000 after acquiring an additional 771,704 shares during the period. Geode Capital Management LLC increased its position in Viking Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 1,994,509 shares of the biotechnology company's stock valued at $70,183,000 after acquiring an additional 385,903 shares during the period. BNP Paribas Financial Markets increased its position in Viking Therapeutics by 536.3% in the 4th quarter. BNP Paribas Financial Markets now owns 992,695 shares of the biotechnology company's stock valued at $34,923,000 after acquiring an additional 836,686 shares during the period. Finally, Raymond James Financial Inc. increased its position in Viking Therapeutics by 16.1% in the 3rd quarter. Raymond James Financial Inc. now owns 954,272 shares of the biotechnology company's stock valued at $25,078,000 after acquiring an additional 131,994 shares during the period. Institutional investors and hedge funds own 76.03% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Ameriprise Financial Inc.在第三季度将其在 Viking Therapeutics 的持仓增加了 41.8%。Ameriprise Financial Inc.现在拥有 2092840 股该生物技术公司的股票，价值 5500 万美元，此前在此期间又收购了 616526 股。Two Sigma Investments LP 在第三季度将其在 Viking Therapeutics 的持仓增加了 58.7%。Two Sigma Investments LP 现在拥有 2085487 股该生物技术公司的股票，价值 54807000 美元，此前在此期间又收购了 771704 股。Geode Capital Management LLC 在第四季度将其在 Viking Therapeutics 的持仓增加了 24.0%。Geode Capital Management LLC 现在拥有 1994509 股该生物技术公司的股票，价值 70183000 美元，此前在此期间又收购了 385903 股。BNP Paribas Financial Markets 在第四季度将其在 Viking Therapeutics 的持仓增加了 536.3%。BNP Paribas Financial Markets 现在拥有 992695 股该生物技术公司的股票，价值 34923000 美元，此前在此期间又收购了 836686 股。最后，Raymond James Financial Inc.在第三季度将其在 Viking Therapeutics 的持仓增加了 16.1%。Raymond James Financial Inc.现在拥有 954272 股该生物技术公司的股票，价值 25078000 美元，此前在此期间又收购了 131994 股。机构投资者和对冲基金持有公司 76.03% 的股份。</p>
</div><h2>Viking Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Viking Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company's pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.</p>
<div class="lb-trans"><p>Viking Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。公司总部位于加利福尼亚州圣地亚哥，其产品线利用小分子方法针对与非酒精性脂肪性肝炎（NASH）、血脂异常、2 型糖尿病和肌肉萎缩疾病相关的激素信号通路。</p>
</div><p>The company's lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.</p>
<div class="lb-trans"><p>该公司的主要项目包括 VK2809，一种设计用于减少肝脏脂肪并改善 NASH 和血脂异常患者的脂质谱的甲状腺激素受体β激动剂，以及 VK5211，一种选择性雄激素受体调节剂（SARM），旨在增强肌肉质量和功能，适用于肌肉萎缩患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Viking Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Viking Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Viking Therapeutics 吗？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Viking Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Viking Therapeutics 并不在名单上。</p>
</div><p>While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viking Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Viking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at BTIG Research

Market Beat

摩根士丹利

纳斯达克 OMX 交易所

阿默普莱斯金融

法国巴黎银行(ADR)

瑞杰金融

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

BTIG 研究公司重申对 Viking 治疗（VKTX）的 “买入” 评级